Hypomyelinating Leukodystrophy 10 (HLD10) — Comprehensive Research Report

1. Disease Information

Overview: Hypomyelinating leukodystrophy 10 (HLD10) is a rare, autosomal recessive neurodevelopmental disorder characterized by postnatally acquired progressive microcephaly, severe global developmental delay, failure to thrive, and hypomyelination with reduced cerebral white-matter volume on brain MRI. It is caused by biallelic loss-of-function variants in PYCR2 (pyrroline-5-carboxylate reductase 2), a mitochondrial enzyme catalyzing the terminal step of proline biosynthesis. The disease spans a phenotypic spectrum from a "milder" hypomyelinating-leukodystrophy presentation to a severe, sometimes lethal syndrome with childhood mortality (Zaki et al., 2016, PMID:27130255).

Key identifiers: - OMIM: #616420 (LEUKODYSTROPHY, HYPOMYELINATING, 10; HLD10) — gene entry PYCR2 616406 - Gene: PYCR2, HGNC:23364, chromosome 1q42.12 - MONDO: MONDO:0014632 - Orphanet: ORPHA:481152 ("PYCR2-related microcephaly-progressive leukoencephalopathy") - Disease Ontology: DOID:0060788 - Inheritance:* Autosomal recessive

Synonyms/alternative names: HLD10; PYCR2-related hypomyelinating leukodystrophy; PYCR2-related microcephaly–progressive leukoencephalopathy; microcephaly, autosomal recessive, PYCR2-related; PYCR2 deficiency; pyrroline-5-carboxylate reductase 2 deficiency.

Evidence basis: Information is drawn from aggregated case-series/cohort publications (11 consanguineous families, 14 patients in Zaki et al. 2016; additional families in Nakayama/Reversade 2015, Meng et al. 2017, and a Thai cohort in 2021) plus individual case reports (Indian, Iranian patients), rather than large-scale EHR/registry data — consistent with an ultra-rare Mendelian disorder (~35 patients reported in the literature as of the 2021 Thai-cohort review).

Sources: - OMIM #616420 - OMIM *616406 PYCR2 - Orphanet ORPHA:481152 - NORD/MONDO summary

2. Etiology

Disease causal factor: HLD10 is caused exclusively by biallelic (homozygous or compound heterozygous) pathogenic variants in PYCR2, encoding a mitochondrial NAD(P)H-dependent oxidoreductase that catalyzes reduction of Δ1-pyrroline-5-carboxylate (P5C) to L-proline — the final step of proline biosynthesis (Nakayama et al., 2015, PMID:25865492).

Genetic risk factors: - Homozygous or compound heterozygous PYCR2 loss-of-function or hypomorphic missense variants. - Reported pathogenic variants include: p.Arg119Cys, p.Arg251Cys (Nakayama 2015); p.Arg266 (most common — found in 5 of 11 Egyptian families), p.Cys232Gly, p.Arg199Trp, p.Val184Ala, p.Gly159Arg, and a 3′ splice-site mutation of intron 2 (Zaki 2016, PMID:27130255); p.Arg119His plus a start-loss variant p.Met1? (compound heterozygous, Indian patient — Srivastava et al. 2021, PMC8143271); p.Val86Gly and p.Val134Met (Thai cohort, with c.400G>A/p.Val134Met found on 3 of 4 mutant alleles studied and estimated to have arisen ~1,450 years ago on a shared 2.3 Mb haplotype, indicating a founder effect in the Thai population) (PMID:34037307). - Consanguinity* is a major risk factor: the majority of reported families are consanguineous (Egyptian, Pakistani, Omani, Palestinian, Iranian pedigrees).

Protective factors: None specifically established. Mouse studies suggest dietary proline supplementation does not rescue and a proline-free diet worsens the phenotype in Pycr2-null mice, implying proline availability modulates (but does not fully explain) severity (Stum et al., 2021, PMID:33734376).

Gene–environment interactions: No established environmental modifiers in humans; the mouse model dietary-proline finding is the only reported gene–diet interaction signal.

Sources: - Nakayama et al. 2015, AJHG (PMC4570282) - Zaki et al. 2016, Ann Neurol (PMC4938747) - Meng et al. 2017, AJMG-A - Thai cohort 2021 (PMID:34037307) - Stum et al. 2021, Genetics (PMID:33734376)

3. Phenotypes

Clinical signs/symptoms (with suggested HPO terms)

Onset/course: Onset is typically in the first year of life (2 months–1 year), following apparently normal early development in some cases (e.g., the Indian case regressed starting at 9 months). The course is progressive: microcephaly worsens postnatally, motor function deteriorates, and in the more severe cohort (Zaki 2016) patients "did not survive beyond the first decade of life," with 5 study patients and 4 deceased siblings dying by age 8, most commonly from pulmonary infections, fever of unknown origin, or failure to thrive — contrasting with the original 2015/milder reports in which "none of the patients died and the longest living survivor was 11 years 6 months old." This establishes a recognized severity spectrum.

QoL impact: Profound — patients typically function at GMFCS level V (inability to sit or stand independently), require full-time care, gastrostomy feeding, and have no expressive language.

Sources: as above (Nakayama 2015, Zaki 2016, Meng 2017, Srivastava 2021/PMC8143271).

4. Genetic/Molecular Information

• Causal gene: PYCR2 (HGNC:23364), OMIM *616406, chr1q42.12.
• Protein function: PYCR2 is a mitochondrial matrix enzyme; together with paralogs PYCR1 and PYCR3, it catalyzes NAD(P)H-dependent reduction of P5C to L-proline, the final and rate-limiting step of proline biosynthesis. PYCR1 loss causes autosomal recessive cutis laxa type IIB (distinct disease), while PYCR2 has "a unique and indispensable role... in the human CNS during development" (Nakayama 2015).
• Variant classification/type: Missense (e.g., p.Arg119Cys, p.Arg251Cys, p.Arg199Trp, p.Val184Ala, p.Gly159Arg, p.Val86Gly, p.Val134Met, p.Arg119His), nonsense (p.Arg266*), and splice-site (3′ splice site, intron 2) variants reported; ClinVar entry VCV000254247 documents at least one classified variant.
• Functional consequences: Missense variants (e.g., R119C, R251C, R199W, R266X) reduce protein stability/abundance without necessarily abolishing mitochondrial localization; disease mechanism is predominantly loss-of-function, though newer structural work (Torii et al. 2022, PMID:36548190/PMC9787162) suggests R119C and R251C also promote aberrant dimeric/trimeric protein complexes (vs normal monomer), implying a possible gain-of-function/dominant-negative structural component in addition to loss of catalytic activity.
• Allele frequency: No specific gnomAD population allele-frequency figure was recovered in this search; PYCR2 pathogenic variants are extremely rare/private, consistent with an ultra-rare autosomal recessive disease (prevalence estimated by some registries at 1 per 200,000–500,000).
• Somatic vs germline: Germline only (constitutional, inherited).
• Founder effect: c.400G>A (p.Val134Met) identified as a likely Thai founder variant, on a shared 2.3 Mb haplotype dated to ~1,450 years ago (PMID:34037307).
• Modifier genes: None specifically established in humans. In Pycr2-null mice, loss of PYCR2 causes secondary loss of PYCR1 protein in brain (and vice versa), indicating the paralogs do not compensate for one another despite similar biochemical activity, and loss of PYCR2 elevates serine hydroxymethyltransferase 2 (SHMT2) and brain glycine levels in both patients and mice — a downstream one-carbon/glycine metabolism perturbation.
• Chromosomal abnormalities: Not applicable — HLD10 is caused by sequence-level PYCR2 variants, not large chromosomal rearrangements.

Suggested ontology terms: HGNC:23364 (PYCR2), GO:0004735 (pyrroline-5-carboxylate reductase activity), GO:0006561 (proline biosynthetic process), GO:0005759 (mitochondrial matrix).

Sources: - Nakayama 2015 (PMC4570282) - Torii et al. 2022, Neurology International (PMC9787162) - ClinVar VCV000254247

5. Environmental Information

No established environmental, lifestyle, or infectious triggers of HLD10 itself (it is a purely Mendelian genetic disorder). The only environmental modulator identified is dietary proline in the Pycr2-null mouse model: a proline-free diet worsened the mutant phenotype, suggesting nutritional proline may partially buffer disease severity, although "proline levels were not reduced, and precursors were not increased in serum" in the mutant mice, so proline auxotrophy per se is not the central mechanism (Stum et al. 2021, PMID:33734376). No infectious agents are implicated in etiology; secondary infections (pulmonary) are a reported cause of death in severely affected children.

6. Mechanism / Pathophysiology

Causal chain (initiating lesion → clinical manifestation):

1. Molecular lesion: Biallelic PYCR2 variants → reduced PYCR2 protein stability/abundance or altered oligomerization (monomer → aberrant dimer/trimer for R119C/R251C) (GO:0004735 pyrroline-5-carboxylate reductase activity).
2. Mitochondrial dysfunction: Loss/dysfunction of PYCR2 → decreased mitochondrial membrane potential (demonstrated by MitoTracker/JC-1 assays) and formation of enlarged mitochondria with increased fusion and decreased fission capacity in patient-mutant-expressing cells (Torii et al. 2022). PYCR2-deficient cells show reduced energy-production capacity.
3. Increased susceptibility to oxidative-stress-induced apoptosis: CRISPR-engineered PYCR2-deficient cells showed significantly more TUNEL-positive apoptotic cells after H2O2 exposure than wild-type, establishing a cytoprotective/anti-apoptotic role for PYCR2 under oxidative stress (Nakayama 2015).
4. Neuronal and oligodendroglial consequences:
5. Primary neuronal dysfunction is thought to drive microcephaly, intellectual disability, epilepsy, and brain atrophy (Zaki 2016 interpretation).
6. Separately, mutant PYCR2 (R119C, R251C) fails to support oligodendroglial cell morphological differentiation, with reduced expression of the myelin markers MBP (myelin basic protein) and CNPase (2′,3′-cyclic-nucleotide 3′-phosphodiesterase) compared to wild type — directly linking mitochondrial dysfunction to the hypomyelination phenotype, since myelination is a highly energy-dependent process (Torii et al. 2022; also emphasized in the Srivastava case report, PMC8143271).
7. Secondary metabolic perturbation: Loss of PYCR2 upregulates SHMT2 and elevates brain glycine in both patients and Pycr2−/− mice, indicating a downstream one-carbon/glycine metabolic disturbance (Stum et al. 2021).
8. Clinical convergence: The combination of primary neuronal vulnerability + impaired oligodendrocyte differentiation/energy failure → progressive microcephaly, developmental regression, seizures, spasticity, and hypomyelination/white-matter volume loss on MRI.

Cell types involved: neurons (CL:0000540), oligodendrocytes/oligodendrocyte precursor cells (CL:0000128 / CL:0002453), fibroblasts (used in functional studies, CL:0000057).

Zebrafish model (developmental confirmation): Morpholino knockdown of pycr1b (zebrafish PYCR2 ortholog) recapitulated microcephaly — reduced head width by 4 dpf and smaller forebrain/midbrain/hindbrain on histology — and was rescued by co-injection of wild-type human PYCR2 mRNA but not by mutant mRNA, confirming variant pathogenicity (Nakayama 2015).

Mouse model (systemic/metabolic confirmation): Pycr2-null mice show weight loss (41–58% less than controls), progressive kyphosis, hind-limb clasping (CNS-attributable), 33% reduced grip strength, 53% loss of total body fat, mild peripheral axonal atrophy, reduced white blood cell counts, and altered lipid metabolism — a broad neurological/neuromuscular and systemic metabolic phenotype, without primary elastin/cutis-laxa-type skin pathology (Stum et al. 2021, PMID:33734376).

Suggested GO terms: GO:0006561 (proline biosynthetic process), GO:0055114 (oxidation-reduction process), GO:0007005 (mitochondrion organization), GO:0006915 (apoptotic process), GO:0022010 (central nervous system myelination), GO:0048709 (oligodendrocyte differentiation).

Sources: - Torii et al. 2022 (PMC9787162) - Nakayama 2015 (PMC4570282) - Stum et al. 2021 (PMID:33734376)

7. Anatomical Structures Affected

• Organ level (primary): Central nervous system — cerebral white matter (UBERON:0002316 white matter), corpus callosum (UBERON:0002336), cerebral cortex (UBERON:0000956), brainstem (UBERON:0002298; "mildly thin" in Nakayama 2015 cohort).
• Secondary/systemic: Musculoskeletal system (muscle atrophy, spasticity, joint contractures); growth/nutrition (failure to thrive); in mouse models, adipose tissue (subcutaneous fat loss) and hematologic system (reduced WBC counts).
• Tissue/cell level: Myelin/white matter tracts; oligodendrocytes (CL:0000128) — impaired differentiation; neurons (CL:0000540) — primary dysfunction; peripheral nerve (mild axonal atrophy in mouse model).
• Subcellular level: Mitochondria (GO:0005739 cellular component; PYCR2 is mitochondrial-matrix resident, GO:0005759) — enlarged, dysmorphic mitochondria with abnormal fusion/fission balance and reduced membrane potential.
• Localization: Bilateral, diffuse (not lateralized) — supratentorial white matter predominantly affected; cerebellum, brainstem, and deep gray nuclei reported as relatively spared/normal in at least one case report (Srivastava 2021).

Suggested UBERON terms: UBERON:0002316 (white matter of central nervous system), UBERON:0002336 (corpus callosum), UBERON:0000955 (brain), UBERON:0001851 (cortex).

8. Temporal Development

• Onset: Congenital-to-early-infantile; head circumference typically normal or near-normal at birth with postnatally acquired progressive microcephaly emerging over the first months of life (onset of clinical presentation generally 2 months to 1 year of age).
• Onset pattern: Insidious/progressive rather than acute.
• Progression: Chronic and progressive — microcephaly deepens, developmental regression may occur (documented from ~9 months in one case), spasticity and seizures often emerge within the first year.
• Disease course: Progressive, non-remitting; no spontaneous or treatment-induced remission reported. Severity is variable — a "milder"/longer-survival phenotype (original 2015 report; longest survivor 11 years 6 months) versus a more severe/lethal phenotype (Zaki 2016 Egyptian/Pakistani cohort; deaths by age 8, no survivors beyond age 10).
• Duration: Chronic, lifelong for survivors; in the more severe cohort, life-limiting (death typically before age 10, from pulmonary infection, fever of unknown origin, or failure to thrive).
• Critical periods: Early infancy appears to be the critical window for both diagnosis (before irreversible regression) and any future intervention, given the "postnatal" (rather than prenatal) onset of microcephaly.

9. Inheritance and Population

• Inheritance pattern: Autosomal recessive (HP:0000007).
• Penetrance: Appears fully penetrant among biallelic carriers in reported families (all homozygous/compound-heterozygous individuals are affected), though disease severity is variable.
• Expressivity: Variable — ranges from a "hypomyelinating leukodystrophy" phenotype with longer survival to a "lethal syndrome of microcephaly and failure to thrive" with early childhood death, even among patients with the same genotype in some instances (e.g., differing outcomes noted between the 2015 and 2016 cohorts).
• Genetic anticipation: Not reported/not applicable (not a repeat-expansion disorder).
• Consanguinity role: Prominent — most reported families are consanguineous (Egyptian, Pakistani, Omani, Palestinian).
• Founder effect: c.400G>A (p.Val134Met) — Thai founder variant, ~1,450 years old, shared 2.3 Mb haplotype (PMID:34037307).
• Epidemiology: Ultra-rare; approximately 35 patients had been reported in the literature as of the 2021 Thai-cohort review. One rare-disease registry estimates prevalence at roughly 1 in 200,000–500,000, though this figure was not independently traced to a primary epidemiological source in this search and should be treated as approximate.
• Population demographics: Reported cases cluster in populations with high consanguinity rates — Egyptian (largest single cohort, Zaki 2016), Pakistani, Omani, Palestinian, Iranian, Indian, and Thai (with an identified founder variant) patients. No clear sex predilection (Zaki 2016 cohort: 7 females, 7 males). Geographic distribution appears broad but ascertainment-biased toward regions/populations with consanguineous marriage practices and access to exome sequencing.

10. Diagnostics

• Genetic testing (primary diagnostic modality): Molecular confirmation via single-gene PYCR2 sequencing, multi-gene leukodystrophy/microcephaly panels, clinical exome sequencing (WES), or whole genome sequencing (WGS) — WES/WGS is typically how cases are identified given the phenotypic overlap with other microcephaly-hypomyelination syndromes. Homozygosity mapping/linkage analysis has been used in consanguineous families (original discovery, Nakayama 2015, LOD score 3.72 on chr1q).
• Chromosomal microarray: Used to exclude copy-number causes of microcephaly as part of a standard microcephaly diagnostic workup, though HLD10 itself is not caused by CNVs.
• Neuroimaging (brain MRI): Central to diagnosis — shows hypomyelination (T2 hyperintense/T1 isointense deep and subcortical white matter), thin corpus callosum, generalized cerebral/cortical atrophy, and a mildly thin brainstem; cerebellum and deep gray nuclei may be relatively spared.
• Laboratory/biochemical tests: Generally unremarkable — "routine serum metabolic profiles were unremarkable," with normal plasma amino acids and urine organic acids in most patients; slightly elevated urinary glutamate noted in 2 families (Zaki 2016). This indicates HLD10 is not reliably detectable by standard metabolic newborn screening or biochemical panels — genetic testing is required.
• Differential diagnosis: Other hypomyelinating leukodystrophies (HLD1–HLD8+, e.g., Pelizaeus-Merzbacher disease/PLP1, GJC2-related HLD2, TUBB4A-related HLD6, POLR3A/B-related HLD7/8), other genetic microcephaly-with-brain-atrophy syndromes, and PYCR1-related autosomal recessive cutis laxa type IIB (which shares proline-pathway biology but is clinically distinguished by cutis laxa/wrinkly skin, which is characteristically absent in HLD10).
• Screening: No population-level or newborn screening program exists for HLD10 (ultra-rare, no biochemical marker); carrier screening/prenatal diagnosis is feasible via targeted PYCR2 variant testing once a familial pathogenic variant is known, particularly relevant given the consanguinity and founder-effect patterns described.

11. Outcome / Prognosis

• Survival/mortality: Highly variable by cohort/severity. In the original 2015 discovery cohort, no reported deaths (longest survivor 11 years 6 months). In the larger 2016 Egyptian/Pakistani cohort (14 patients, 11 families), "patients did not survive beyond the first decade of life" — 5 study patients plus 4 deceased siblings died by age 8; causes of death included pulmonary infections, fever of unknown origin, and failure to thrive.
• Morbidity/function: Profound and lifelong — patients typically achieve, at best, GMFCS level V functional status (unable to sit or stand independently), with global developmental delay/intellectual disability, absent or minimal expressive language, and dependence on caregivers for all activities of daily living.
• Complications: Recurrent pulmonary infections (aspiration-related, given dysphagia/hypotonia), seizures, failure to thrive/malnutrition, spasticity-related joint contractures.
• Recovery potential: None described — the disease course is progressive/degenerative rather than static; no reports of developmental catch-up.
• Prognostic factors: Genotype-severity correlation is not cleanly established, but truncating (nonsense/splice) variants and the specific cohort/ethnic background (Egyptian severe cohort vs. original milder cohort) have been associated with differing survival outcomes in the literature to date; this remains an area of uncertainty given small sample sizes.

12. Treatment

No disease-modifying or curative therapy exists for HLD10. Management is entirely supportive/symptomatic, consistent with hypomyelinating leukodystrophies generally:

• Pharmacotherapy for symptoms:
• Anti-seizure medications for epilepsy (NCIT:C15986 Pharmacotherapy; specific agent depends on seizure semiology).
• Anti-spasticity agents (e.g., baclofen, tizanidine — general class) for spasticity management.
• Surgical/interventional:
• Gastrostomy tube placement (NCIT:C15329 Surgical Procedure) for severe dysphagia/failure to thrive.
• Orthopedic surgery for joint contractures/scoliosis (NCIT:C16186 Orthopedic Surgical Procedure).
• Rehabilitative/supportive care:
• Physical therapy (NCIT:C15302) for spasticity/mobility and orthotic bracing.
• Occupational and speech/communication therapy, assistive communication devices.
• Special education services.
• Nutritional support (NCIT:C15433 or NCIT:C15447 Dietary Intervention) for failure to thrive.
• Wheelchair seating/positioning to manage scoliosis risk.
• Monitoring: Serial brain MRI to track hypomyelination/atrophy progression; ongoing surveillance for neurologic complications (per general hypomyelinating-leukodystrophy management literature).
• Experimental/investigational: No PYCR2-specific gene therapy, enzyme replacement, or targeted molecular therapy has reached clinical trials as of this search. General hypomyelinating-leukodystrophy therapeutic development (e.g., intrathecal approaches in other HLDs such as metachromatic leukodystrophy) is not yet applicable to HLD10 specifically. No ClinicalTrials.gov-registered HLD10/PYCR2-specific interventional trial was identified in this search.
• Genetic counseling: Recommended for families given autosomal recessive inheritance, high consanguinity prevalence, and availability of carrier/prenatal testing once a familial variant is identified.

Sources: - Alex TLC — Hypomyelinating Leukodystrophies overview - General HLD management literature (Pouwels et al. 2014, Ann Neurol, translational review)

13. Prevention

• Primary prevention: Genetic counseling and carrier screening in populations/families with known consanguinity or a previously identified familial PYCR2 variant; preimplantation genetic diagnosis (PGD) or prenatal diagnosis is technically feasible once the familial variant is known, though not specifically reported as routinely offered for HLD10 in the literature reviewed.
• Secondary prevention: Early genetic diagnosis in at-risk families (e.g., after an index case) allows earlier initiation of supportive care and family planning counseling.
• Tertiary prevention: Proactive management of complications — nutritional support/gastrostomy to prevent aspiration and failure-to-thrive complications, seizure control, and infection surveillance/prophylaxis (given pulmonary infection as a leading cause of death in the severe cohort).
• Immunization: No disease-specific vaccine strategy; standard childhood immunizations remain important given increased vulnerability to pulmonary infection.
• Public health/environmental interventions: Not applicable — no environmental modifiable risk factor identified.

14. Other Species / Natural Disease

No naturally occurring PYCR2-associated disease has been reported in companion animals or wildlife in the sources reviewed. All animal data derive from engineered/induced models (see Model Organisms, below), not spontaneous veterinary disease. PYCR2 orthologs are broadly conserved across vertebrates (zebrafish pycr1b functions as the PYCR2 ortholog; mouse Pycr2 is a direct ortholog).

15. Model Organisms

Zebrafish (induced, morpholino knockdown)

• Model: Morpholino-based knockdown of pycr1b (the zebrafish PYCR2 ortholog).
• Phenotype recapitulation: Small head size evident by 1 day post-fertilization; significantly reduced maximum head width by 4 dpf; histologically smaller forebrain, midbrain, and hindbrain — recapitulating the human microcephaly phenotype.
• Rescue experiment: Co-injection of wild-type human PYCR2 mRNA rescued the microcephaly phenotype, whereas mutant (patient-variant) mRNAs showed absent or only partial rescue — providing strong functional confirmation of variant pathogenicity (Nakayama et al. 2015, PMID:25865492).
• Limitations: Morpholino knockdown models transient, whole-embryo loss of function rather than the postnatal, progressive, CNS-restricted human phenotype; does not model hypomyelination, myelin markers, or longer-term neurodevelopmental/behavioral outcomes.

Mouse (Pycr2 knockout, ENU/targeted null allele)

• Model: Recessive loss-of-function Pycr2 mutant mice (Stum et al. 2021, PMID:33734376), studied alongside a Pycr1-null model.
• Phenotype recapitulation: Weight loss (41–58% less than controls at 3 and 9 months), progressive kyphosis, hind-limb clasping (attributed to CNS rather than peripheral dysfunction), 33% reduced grip strength, 53% total-body-fat loss, mild peripheral axonal atrophy without denervation, reduced white blood cell counts, and altered lipid metabolism — broadly recapitulating the neurological/neuromuscular and systemic-metabolic character of human HLD10, though not modeling frank microcephaly or hypomyelination directly in the reported characterization.
• Mechanistic insights: Serum proline levels were not reduced and proline precursors were not increased despite enzyme loss, arguing against simple proline auxotrophy as the core mechanism; a proline-free diet worsened the phenotype. Brain loss of PYCR2 also caused secondary loss of PYCR1 protein (and vice versa), showing the paralogs do not compensate for one another in vivo. Elevated brain glycine and increased SHMT2 were observed in both patients and mutant mice, pointing to a shared downstream one-carbon/glycine-metabolism perturbation.
• Limitations: No elastin/cutis-laxa-type skin phenotype was observed despite subcutaneous fat loss, distinguishing the mouse Pycr2-null phenotype from human PYCR1-related cutis laxa; the degree to which the mouse model reproduces the specific hypomyelination and severe microcephaly of human HLD10 was not fully characterized in the source reviewed — flagged here as a candidate HUMAN_MODEL_MISMATCH consideration for curation (murine CNS phenotype centers on kyphosis/clasping/weight loss rather than confirmed hypomyelination).

Cellular/in vitro models

• CRISPR-engineered PYCR2-deficient human cell lines: decreased mitochondrial membrane potential, increased apoptosis under oxidative stress (H2O2/TUNEL assay) (Nakayama 2015).
• Patient-variant (R119C, R251C) expression studies: enlarged mitochondria with altered fusion/fission dynamics, reduced membrane potential, and failure of oligodendroglial morphological differentiation (reduced MBP/CNPase) — directly modeling the hypomyelination mechanism at the cellular level (Torii et al. 2022, PMID:36548190/PMC9787162).

Resources: MGI (Pycr2 allele records), ZFIN (zebrafish pycr1b), Alliance of Genome Resources.

Summary of Key Evidence Citations (PMIDs)

Note on gaps: This report is compiled from web-accessible abstracts and secondary summaries (PubMed/PMC/OMIM/Orphanet listings); several primary full-text sources (OMIM #616420 full clinical synopsis, original PubMed abstract pages) returned bot-protection errors during retrieval and could not be quoted directly — figures and quotes above are drawn from PMC full-text mirrors and search-engine-extracted summaries where direct fetch failed. A precise gnomAD population allele-frequency figure for specific PYCR2 pathogenic variants was not located in this search and should be independently verified (e.g., directly via gnomad.broadinstitute.org) before being cited as a hard prevalence/carrier-frequency figure in a knowledge-base entry.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.